Innovent Reports the First Patient Dosing of IBI333 in P-I Clinical Study for Neovascular Age-Related Macular Degeneration
- The first participant has been dosed in the P-I trial of IBI333, a recombinant anti-VEGF–A and anti-VEGF-C bispecific fusion protein in patients with nAMD
- The trial focuses to evaluate the safety and tolerability of IBI333 (IVT) in patients with nAMD & will provide more encouraging innovative therapies to the clinic & benefit nAMD patients. In preclinical studies, IBI333 has proven effective at preventing angiogenesis and vascular leakage and has exhibited a dose-dependent efficacy
- IBI333 is a recombinant anti-VEGF-A and anti-VEGF-C bispecific fusion protein that has been developed by Innovent. The therapy is designed to bind and neutralize the activities of VEGF-A and VEGF-C
Ref: PRNewswire | Image: Innovent
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.